Focus Partners Advisor Solutions LLC Increases Position in Danaher Corporation $DHR

Key Points

• Focus Partners Advisor Solutions LLC increased its stake in Danaher Corporation by 21.9%, now owning 10,042 shares valued at approximately $2.06 million.
• Insiders, including Director Teri List, have sold shares, with a notable transaction involving the sale of 2,778 shares at an average price of $211.06.
• The stock has received multiple upgrades from brokerages, including a shift from a "hold" to a "buy" rating by Wall Street Zen and a consensus target price of $247.61.

Focus Partners Advisor Solutions LLC raised its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 21.9% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,042 shares of the conglomerate's stock after purchasing an additional 1,805 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Danaher were worth $2,059,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after buying an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after buying an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after buying an additional 194,466 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Danaher by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock worth $1,303,163,000 after buying an additional 579,046 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after buying an additional 1,450,703 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.10% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DHR. Evercore ISI dropped their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Wells Fargo & Company dropped their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Robert W. Baird upped their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. UBS Group dropped their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a report on Tuesday. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus price target of $246.35.

Danaher Stock Performance

DHR stock traded up $1.29 during midday trading on Friday, reaching $200.32. 2,837,584 shares of the company's stock traded hands, compared to its average volume of 2,859,442. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The stock has a market cap of $143.44 billion, a P/E ratio of 42.62, a PEG ratio of 2.79 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock's 50-day moving average is $201.93 and its 200 day moving average is $199.37.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The firm's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.